Antibody response to SARS-CoV-2 in people living with HIV.
作者信息
Yamamoto Shinya, Saito Makoto, Nagai Etsuko, Toriuchi Keiko, Nagai Hiroyuki, Yotsuyanagi Hiroshi, Nakagama Yu, Kido Yasutoshi, Adachi Eisuke
机构信息
Department of Infectious Diseases and Applied Immunology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Parasitology, Graduate Scholl of Medicine, Osaka City University, Osaka, Japan.
出版信息
J Microbiol Immunol Infect. 2021 Feb;54(1):144-146. doi: 10.1016/j.jmii.2020.09.005. Epub 2020 Oct 2.
Abstract
摘要
相似文献
1
Antibody response to SARS-CoV-2 in people living with HIV.
J Microbiol Immunol Infect. 2021 Feb;54(1):144-146. doi: 10.1016/j.jmii.2020.09.005. Epub 2020 Oct 2.
2
Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Viruses. 2022 Jan 28;14(2):277. doi: 10.3390/v14020277.
3
SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
Lancet HIV. 2021 Jun;8(6):e334-e341. doi: 10.1016/S2352-3018(21)00072-2. Epub 2021 Apr 29.
4
SARS-CoV-2 seroprevalence among people living with HIV in the German HIV-1 Seroconverter Cohort, 2020-2022.
BMC Infect Dis. 2024 Nov 1;24(1):1228. doi: 10.1186/s12879-024-10119-3.
5
SARS-CoV-2 seroprevalence and associated factors among people living with HIV in Sierra Leone.
Immun Inflamm Dis. 2024 Jul;12(7):e1338. doi: 10.1002/iid3.1338.
6
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial.
J Infect. 2024 Dec;89(6):106285. doi: 10.1016/j.jinf.2024.106285. Epub 2024 Sep 27.
7
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Viruses. 2024 Apr 24;16(5):661. doi: 10.3390/v16050661.
8
Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
Int Immunopharmacol. 2022 Jan;102:108383. doi: 10.1016/j.intimp.2021.108383. Epub 2021 Nov 18.
9
Seroconversion against SARS-CoV-2 occurred after the recovery in patients with COVID-19.
J Med Virol. 2021 Feb;93(2):692-694. doi: 10.1002/jmv.26495. Epub 2020 Sep 29.
10
Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
Front Immunol. 2021 Sep 3;12:705441. doi: 10.3389/fimmu.2021.705441. eCollection 2021.
引用本文的文献
1
Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.
AIDS Res Ther. 2024 Jan 3;21(1):1. doi: 10.1186/s12981-023-00590-4.
2
Anti-SARS-CoV-2 Antibody Level Is Associated with a History of COVID-19 Infection and mRNA Vaccination in Patients with Diabetes.
Vaccines (Basel). 2023 Aug 27;11(9):1424. doi: 10.3390/vaccines11091424.
3
Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19.
JCI Insight. 2022 Nov 8;7(21):e158402. doi: 10.1172/jci.insight.158402.
4
A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV.
Front Med (Lausanne). 2022 Mar 7;9:768138. doi: 10.3389/fmed.2022.768138. eCollection 2022.
5
Case series of HIV SARS-CoV-2 co-infection in Chinese adults.
J Clin Virol Plus. 2022 Feb;2(1):100062. doi: 10.1016/j.jcvp.2022.100062. Epub 2022 Jan 10.
6
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.
Nat Commun. 2021 Oct 29;12(1):6250. doi: 10.1038/s41467-021-26479-2.
7
HIV and COVID-19: review of clinical course and outcomes.
HIV Res Clin Pract. 2021 Aug;22(4):102-118. doi: 10.1080/25787489.2021.1975608. Epub 2021 Sep 12.
8
Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave.
Clin Infect Dis. 2022 Aug 24;75(1):e249-e256. doi: 10.1093/cid/ciab758.
9
COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis.
Int J Environ Res Public Health. 2021 Mar 30;18(7):3554. doi: 10.3390/ijerph18073554.
本文引用的文献
1
Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.
Emerg Infect Dis. 2020 Oct;26(10):2484-2487. doi: 10.3201/eid2610.202211. Epub 2020 Jun 24.
2
Antibody Profiles in Mild and Severe Cases of COVID-19.
Clin Chem. 2020 Aug 1;66(8):1102-1104. doi: 10.1093/clinchem/hvaa137.
3
One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4 T-cell count.
Int J Infect Dis. 2020 Jul;96:148-150. doi: 10.1016/j.ijid.2020.04.060. Epub 2020 Apr 23.
4
The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression.
Nat Immunol. 2013 Dec;14(12):1256-65. doi: 10.1038/ni.2746. Epub 2013 Oct 27.
5
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons.
Clin Infect Dis. 2005 Oct 1;41(7):1045-8. doi: 10.1086/433180. Epub 2005 Aug 22.
Zotero 插件